Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients.
Craniopharyngioma is a rare dysontogenetic benign tumor. Patients frequently suffer from endocrine deficiencies, sleep disturbances, and obesity due to pituitary and hypothalamic lesions. A self-assessment daytime sleepiness questionnaire (German version of the Epworth Sleepiness Scale) was used to evaluate 79 patients with childhood craniopharyngioma. Because hypothalamic lesions may explain daytime sleepiness in craniopharyngioma patients, salivary melatonin and cortisol concentrations were examined in obese and nonobese craniopharyngioma patients (n = 79), patients with hypothalamic pilocytic astrocytoma (n = 19), and control subjects (n = 30). Using a general linear model procedure analyzing the influence of body mass index (BMI) and tumor diagnosis on diurnal salivary melatonin, we found that morning salivary melatonin levels were related to BMI (by F test, P = 0.004) and tumor diagnosis (by F test, P = 0.032). Also for nighttime salivary melatonin levels significant relations with BMI (by F test, P < 0.001) and tumor diagnosis (by F test, P = 0.025) were detectable. Melatonin concentrations in saliva of craniopharyngioma patients collected at night or in the morning showed a negative correlation (night: Spearman's rho = -0.42; P = 0.001; morning: Spearman's rho = -0.31; P = 0.020) with the patient's Epworth Sleepiness Scale score. Severely obese craniopharyngioma patients and severely obese hypothalamic tumor patients had similar patterns of melatonin secretion. Differences in terms of diurnal salivary cortisol concentrations were not detectable when patient groups and controls were compared. We speculate that hypothalamic lesions might be responsible for both obesity and daytime sleepiness. As decreased nocturnal melatonin levels were associated with increased daytime sleepiness, BMI, and hypothalamic tumor diagnosis, further studies on the beneficial effects of melatonin substitution on daytime sleepiness and weight control in these patients are warranted.
Müller
Hermann L
HL
Department of Pediatrics, Zentrum für Kinder- und Jugendmedizin, Klinikum Oldenburg gGmbH (H.L.M.), 26133 Oldenburg, Germany. mueller.hermann@kliniken-oldenburg.de
Handwerker
Georg
G
Wollny
Brigitte
B
Faldum
Andreas
A
Sörensen
Niels
N
D000293:Adolescent; D000328:Adult; D001254:Astrocytoma / Q000378:metabolism / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D003397:Craniopharyngioma / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000032:analysis; D007029:Hypothalamic Neoplasms / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008550:Melatonin / Q000032:analysis / Q000378:metabolism*; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D012463:Saliva / Q000737:chemistry; D012894:Sleep Stages / Q000502:physiology*; D011795:Surveys and Questionnaires
D008550:Melatonin; D006854:Hydrocortisone